{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:05:20Z","timestamp":1751083520653,"version":"3.41.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jpet.2025.103589","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T22:58:14Z","timestamp":1745621894000},"page":"103589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting kinase target inhibition level for efficacy in rheumatoid arthritis: A translational approach based on collagen-induced arthritis rodent studies"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1825-2401","authenticated-orcid":false,"given":"Rui","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Gifford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Symanowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara M.M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0883-9076","authenticated-orcid":false,"given":"Martin","family":"Hegen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.jpet.2025.103589_bib1","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/rheumatology\/keaa893","article-title":"Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis","volume":"60","author":"Avci","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpet.2025.103589_bib2","article-title":"Therapeutic advances in rheumatoid arthritis","volume":"384","author":"Brown","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jpet.2025.103589_bib3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41577-023-00877-7","article-title":"Protein kinases: drug targets for immunological disorders","volume":"23","author":"Castelo-Soccio","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jpet.2025.103589_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11095-019-2752-y","article-title":"Population pharmacokinetics, efficacy exposure-response analysis, and model-based meta-analysis of fenebrutinib in subjects with rheumatoid arthritis","volume":"37","author":"Chan","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.jpet.2025.103589_bib5","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study)","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpet.2025.103589_bib6","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2665-9913(23)00089-9","article-title":"Evaluation of BMS-986142, a reversible Bruton\u2019s tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study","volume":"5","author":"Conaghan","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jpet.2025.103589_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/jpet.104.077792","article-title":"Nociceptive sensitivity and opioid antinociception and antihyperalgesia in Freund\u2019s adjuvant-induced arthritic male and female rats","volume":"313","author":"Cook","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103589_bib8","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: a potent, selective, and noncovalent Bruton\u2019s tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpet.2025.103589_bib9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13075-019-2008-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects","volume":"21","author":"Danto","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"S10","key":"10.1016\/j.jpet.2025.103589_bib10","first-page":"1","article-title":"Efficacy and safety of the selective interleukin-1 receptor associated kinase 4 inhibitor, PF-06650833, in patients with active rheumatoid arthritis and inadequate response to methotrexate (Abstract)","volume":"71","author":"Danto","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpet.2025.103589_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.113.209304","article-title":"Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis","volume":"348","author":"Dowty","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103589_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jpet.2025.103589_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpet.2025.103589_bib14","doi-asserted-by":"crossref","first-page":"8974","DOI":"10.1038\/s41598-020-65762-y","article-title":"Demonstration of in vitro to in vivo translation of a TYK2 inhibitor that shows cross species potency differences","volume":"10","author":"Gerstenberger","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2025.103589_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181782","article-title":"Bruton\u2019s tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care","volume":"12","author":"Gillooly","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2025.103589_bib16","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1136\/ard.2007.076430","article-title":"Utility of animal models for identification of potential therapeutics for rheumatoid arthritis","volume":"67","author":"Hegen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpet.2025.103589_bib17","first-page":"318","article-title":"The mechanism of action of tofacitinib \u2013 an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jpet.2025.103589_bib18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpet.2025.103589_bib19","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","article-title":"Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration","volume":"81","author":"Lauper","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpet.2025.103589_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00228-017-2226-2","article-title":"Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants","volume":"73","author":"Lee","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpet.2025.103589_bib21","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1080\/13102818.2022.2027815","article-title":"Gender differences in collagen-induced arthritis (CIA) in mice","volume":"35","author":"Marinov","year":"2021","journal-title":"Biotechnol Biotechnol Equip"},{"key":"10.1016\/j.jpet.2025.103589_bib22","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1021\/acs.jmedchem.9b01365","article-title":"Dose predictions for drug design","volume":"63","author":"Maurer","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpet.2025.103589_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection","volume":"54","author":"Namour","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpet.2025.103589_bib24","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1345\/aph.1L268","article-title":"Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis","volume":"42","author":"Plushner","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpet.2025.103589_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: Making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpet.2025.103589_bib26","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jpet.2025.103589_bib27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2307\/2297773","article-title":"On least-squares estimation when the dependent variable is grouped","volume":"50","author":"Stewart","year":"1983","journal-title":"Rev Econ Stud"},{"key":"10.1016\/j.jpet.2025.103589_bib28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpet.2025.103589_bib29","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jpet.2025.103589_bib30","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/art.41953","article-title":"The interleukin-1 receptor-associated kinase 4 inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatic disease and in humans enrolled in a randomized clinical trial","volume":"73","author":"Winkler","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpet.2025.103589_bib31","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1124\/jpet.118.255562","article-title":"Exposure-effect relationships in established rat adjuvant-induced and collagen-induced arthritis: a translational pharmacokinetic-pharmacodynamic analysis","volume":"369","author":"Wong","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103589_bib32","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/art.22452","article-title":"Blockade of the interleukin-21\/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis","volume":"56","author":"Young","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpet.2025.103589_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2021","journal-title":"Nat Rev Drug Discov"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T10:17:52Z","timestamp":1751019472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525398022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0022356525398022"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103589","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting kinase target inhibition level for efficacy in rheumatoid arthritis: A translational approach based on collagen-induced arthritis rodent studies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103589"}}